CA Patent

CA2568744A1 — Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins

Assigned to Bausch Health Companies Inc · Expires 2005-12-22 · 20y expired

What this patent protects

The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin pene…

USPTO Abstract

The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOLTM to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2568744A1
Jurisdiction
CA
Classification
—
Expires
2005-12-22
Drug substance claim
No
Drug product claim
No
Assignee
Bausch Health Companies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.